Chemical: Drug
cetuximab

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for cetuximab and EGFR,KRAS
  2. EMA Label for cetuximab and EGFR,KRAS
  3. PMDA Label for cetuximab and EGFR,KRAS
  4. HCSC Label for cetuximab and EGFR,KRAS

last updated 10/25/2013

1. FDA Label for cetuximab and EGFR,KRAS

Genetic testing required

Summary

Cetuximab is used in alone or in combination therapy to treat advanced squamous cell carcinoma of the head and neck and to treat K-Ras mutation-negative, EGFR expressing metastatic colorectal cancer. In cases of colorectal cancer, the label states "Determine K-Ras mutation and EGFR-expression status using FDA-approved tests prior to initiating treatment."

There's more of this label. Read more.


last updated 10/25/2013

2. EMA Label for cetuximab and EGFR,KRAS

Genetic testing required

Summary

The EMA European Public Assessment Report (EPAR) highlights information regarding the contraindication of Cetuximab (Erbitux) in colorectal cancer patients with tumors with KRAS mutations or if tumor status is not known.

There's more of this label. Read more.


last updated 01/26/2015

3. PMDA Label for cetuximab and EGFR,KRAS

Genetic testing required

Summary

The PMDA package insert for cetuximab states that it is indicated for individuals with epidermal growth factor receptor (EGFR)-expressing colorectal cancer. It also notes that KRAS mutational status should be considered for selecting patients with EGFR-expressing colorectal cancer.

There's more of this label. Read more.


last updated 06/08/2015

4. HCSC Label for cetuximab and EGFR,KRAS

Genetic testing required

Summary

The product monograph for cetuximab (ERBITUX) states that it is indicated for treatment of EGFR-expressing K-ras wild-type metastatic colorectal carcinoma.

There's more of this label. Read more.


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for cetuximab

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No Clinical Annotations available VA
rs10034692 NC_000004.11:g.75419787A>G, NC_000004.12:g.74554070A>G, NW_003571035.1:g.37578A>G, rs61009756
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1017733 NC_000004.11:g.75252350C>T, NC_000004.12:g.74386633C>T, NM_001432.2:c.*1825C>T, rs60002456, rs61714962
C > T
SNP
rs112445441 NC_000012.11:g.25398281C>A, NC_000012.11:g.25398281C>G, NC_000012.11:g.25398281C>T, NC_000012.12:g.25245347C>A, NC_000012.12:g.25245347C>G, NC_000012.12:g.25245347C>T, NG_007524.1:g.10574G>A, NG_007524.1:g.10574G>C, NG_007524.1:g.10574G>T, NM_004985.4:c.38G>A, NM_004985.4:c.38G>C, NM_004985.4:c.38G>T, NM_033360.3:c.38G>A, NM_033360.3:c.38G>C, NM_033360.3:c.38G>T, NP_004976.2:p.Gly13Ala, NP_004976.2:p.Gly13Asp, NP_004976.2:p.Gly13Val, NP_203524.1:p.Gly13Ala, NP_203524.1:p.Gly13Asp, NP_203524.1:p.Gly13Val, XM_005253365.1:c.38G>A, XM_005253365.1:c.38G>C, XM_005253365.1:c.38G>T, XM_006719069.2:c.38G>A, XM_006719069.2:c.38G>C, XM_006719069.2:c.38G>T, XM_011520653.1:c.38G>A, XM_011520653.1:c.38G>C, XM_011520653.1:c.38G>T, XP_005253422.1:p.Gly13Ala, XP_005253422.1:p.Gly13Asp, XP_005253422.1:p.Gly13Val, XP_006719132.1:p.Gly13Ala, XP_006719132.1:p.Gly13Asp, XP_006719132.1:p.Gly13Val, XP_011518955.1:p.Gly13Ala, XP_011518955.1:p.Gly13Asp, XP_011518955.1:p.Gly13Val
C > A
C > G
C > T
SNP
G13A/D/V
No VIP available No Clinical Annotations available VA
rs11568315
(CA)16 > (CA)14
(CA)16 > (CA)15
(CA)16 > (CA)17
(CA)16 > (CA)18
(CA)16 > (CA)19
(CA)16 > (CA)20
(CA)16 > (CA)21
(CA)16 > (CA)22
(CA)16 > (CA)23
(CA)16 > (CA)9
microsatellite
No VIP available No Clinical Annotations available VA
rs11568972 NC_000004.11:g.110889007A>C, NC_000004.12:g.109967851A>C, NG_011441.1:g.59968A>C, NM_001178130.2:c.1576-1120A>C, NM_001178131.2:c.1450-1120A>C, NM_001963.5:c.1576-1120A>C, XM_005262796.1:c.1576-1120A>C, XM_005262796.2:c.1576-1120A>C, XM_005262797.1:c.1450-1120A>C, XM_005262797.2:c.1450-1120A>C, XM_005262798.1:c.1576-1120A>C, XM_005262798.2:c.1576-1120A>C, XM_005262799.1:c.1576-1120A>C, XM_005262800.1:c.1576-1120A>C, XM_005262800.2:c.1576-1120A>C, XM_005262801.1:c.1576-1120A>C, XM_005262801.2:c.1576-1120A>C, XM_005262802.1:c.1576-1120A>C, XM_005262802.2:c.1576-1120A>C, XM_006714124.2:c.1576-1120A>C, XM_011531707.1:c.1465-1120A>C, XM_011531708.1:c.1576-1120A>C, XM_011531709.1:c.1576-1120A>C, XR_427532.2:n.2029-1120A>C, XR_938699.1:n.2029-1120A>C
A > C
SNP
No VIP available No Clinical Annotations available VA
rs11568993 NC_000004.11:g.110897315C>T, NC_000004.12:g.109976159C>T, NG_011441.1:g.68276C>T, NM_001178130.2:c.1977C>T, NM_001178131.2:c.1851C>T, NM_001963.5:c.1977C>T, NP_001171601.1:p.Cys659=, NP_001171602.1:p.Cys617=, NP_001954.2:p.Cys659=, XM_005262796.1:c.1977C>T, XM_005262796.2:c.1977C>T, XM_005262797.1:c.1851C>T, XM_005262797.2:c.1851C>T, XM_005262798.1:c.1977C>T, XM_005262798.2:c.1977C>T, XM_005262799.1:c.1977C>T, XM_005262800.1:c.1977C>T, XM_005262800.2:c.1977C>T, XM_005262801.1:c.1977C>T, XM_005262801.2:c.1977C>T, XM_005262802.1:c.1977C>T, XM_005262802.2:c.1977C>T, XM_006714124.2:c.1977C>T, XM_011531707.1:c.1866C>T, XM_011531708.1:c.1977C>T, XM_011531709.1:c.1977C>T, XP_005262853.1:p.Cys659=, XP_005262854.1:p.Cys617=, XP_005262855.1:p.Cys659=, XP_005262856.1:p.Cys659=, XP_005262857.1:p.Cys659=, XP_005262858.1:p.Cys659=, XP_005262859.1:p.Cys659=, XP_006714187.1:p.Cys659=, XP_011530009.1:p.Cys622=, XP_011530010.1:p.Cys659=, XP_011530011.1:p.Cys659=, XR_427532.2:n.2430C>T, XR_938699.1:n.2430C>T, rs58950882
C > T
SNP
C659C
No VIP available No Clinical Annotations available VA
rs11725706 NC_000004.11:g.75328108G>A, NC_000004.12:g.74462391G>A, rs57576418
G > A
SNP
No VIP available CA VA
rs11942466 NC_000004.11:g.75422078C>A, NC_000004.12:g.74556361C>A, NW_003571035.1:g.39869C>A
C > A
SNP
No VIP available No Clinical Annotations available VA
rs11997869 NC_000008.10:g.6638464C>G, NC_000008.11:g.6780943C>G
C > A
C > G
SNP
rs121913529 NC_000012.11:g.25398284C>A, NC_000012.11:g.25398284C>G, NC_000012.11:g.25398284C>T, NC_000012.12:g.25245350C>A, NC_000012.12:g.25245350C>G, NC_000012.12:g.25245350C>T, NG_007524.1:g.10571G>A, NG_007524.1:g.10571G>C, NG_007524.1:g.10571G>T, NM_004985.4:c.35G>A, NM_004985.4:c.35G>C, NM_004985.4:c.35G>T, NM_033360.3:c.35G>A, NM_033360.3:c.35G>C, NM_033360.3:c.35G>T, NP_004976.2:p.Gly12Ala, NP_004976.2:p.Gly12Asp, NP_004976.2:p.Gly12Val, NP_203524.1:p.Gly12Ala, NP_203524.1:p.Gly12Asp, NP_203524.1:p.Gly12Val, XM_005253365.1:c.35G>A, XM_005253365.1:c.35G>C, XM_005253365.1:c.35G>T, XM_006719069.2:c.35G>A, XM_006719069.2:c.35G>C, XM_006719069.2:c.35G>T, XM_011520653.1:c.35G>A, XM_011520653.1:c.35G>C, XM_011520653.1:c.35G>T, XP_005253422.1:p.Gly12Ala, XP_005253422.1:p.Gly12Asp, XP_005253422.1:p.Gly12Val, XP_006719132.1:p.Gly12Ala, XP_006719132.1:p.Gly12Asp, XP_006719132.1:p.Gly12Val, XP_011518955.1:p.Gly12Ala, XP_011518955.1:p.Gly12Asp, XP_011518955.1:p.Gly12Val, rs121913531, rs121913534
C > A
C > G
C > T
SNP
G12A/D/V
No VIP available CA VA
rs13104811 NC_000004.11:g.75395312G>A, NC_000004.12:g.74529595G>A, NW_003571035.1:g.13103G>A
G > A
SNP
No VIP available CA VA
rs1353295 NC_000004.11:g.75329122G>A, NC_000004.12:g.74463405G>A, rs1797595, rs59361263
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1570360 NC_000006.11:g.43737830A>G, NC_000006.12:g.43770093A>G, NG_008732.1:g.4878A>G, NM_001025366.2:c.-614A>G, NM_001025367.2:c.-614A>G, NM_001025368.2:c.-614A>G, NM_001025369.2:c.-614A>G, NM_001025370.2:c.-614A>G, NM_001033756.2:c.-614A>G, NM_001171622.1:c.-614A>G, NM_001171623.1:c.-1154A>G, NM_001171624.1:c.-1154A>G, NM_001171625.1:c.-1154A>G, NM_001171626.1:c.-1154A>G, NM_001171627.1:c.-1154A>G, NM_001171628.1:c.-1154A>G, NM_001171629.1:c.-1154A>G, NM_001171630.1:c.-1154A>G, NM_001204384.1:c.-1154A>G, NM_001204385.1:c.-614A>G, NM_001287044.1:c.-2027A>G, NM_001317010.1:c.-1154A>G, NM_003376.5:c.-614A>G, XM_005249363.1:c.-2027A>G, rs36208386, rs58036053
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1801274 NC_000001.10:g.161479745A>G, NC_000001.11:g.161509955A>G, NG_012066.1:g.9541A>G, NM_001136219.1:c.500A>G, NM_021642.3:c.497A>G, NP_001129691.1:p.His167Arg, NP_067674.2:p.His166Arg, XM_005244960.1:c.500A>G, XM_011509287.1:c.500A>G, XM_011509288.1:c.497A>G, XM_011509289.1:c.500A>G, XM_011509290.1:c.500A>G, XM_011509291.1:c.500A>G, XP_005245017.1:p.His167Arg, XP_011507589.1:p.His167Arg, XP_011507590.1:p.His166Arg, XP_011507591.1:p.His167Arg, XP_011507592.1:p.His167Arg, XP_011507593.1:p.His167Arg, rs16830404, rs17851761, rs386545630, rs52796393, rs58440466
A > G
SNP
H167R
No VIP available No Clinical Annotations available VA
rs2073016 NC_000006.11:g.41020922T>C, NC_000006.12:g.41053183T>C, NM_006789.3:c.-165T>C
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2074390 NC_000004.11:g.110910016G>A, NC_000004.12:g.109988860G>A, NG_011441.1:g.80977G>A, NM_001178130.2:c.2734+151G>A, NM_001178131.2:c.2608+151G>A, NM_001963.5:c.2734+151G>A, XM_005262796.1:c.2734+151G>A, XM_005262796.2:c.2734+151G>A, XM_005262797.1:c.2608+151G>A, XM_005262797.2:c.2608+151G>A, XM_005262798.1:c.2492-4387G>A, XM_005262798.2:c.2492-4387G>A, XM_005262799.1:c.2734+151G>A, XM_005262800.1:c.2492-4387G>A, XM_005262800.2:c.2492-4387G>A, XM_005262801.1:c.2491+5319G>A, XM_005262801.2:c.2491+5319G>A, XM_006714124.2:c.2734+151G>A, XM_011531707.1:c.2623+151G>A, XM_011531708.1:c.2734+151G>A, XR_427532.2:n.3187+151G>A, XR_938699.1:n.3187+151G>A, rs17253568, rs58663575
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2132065 NC_000004.11:g.75325304A>T, NC_000004.12:g.74459587A>T, rs59208677
A > T
SNP
No VIP available No Clinical Annotations available VA
rs2227983 NC_000007.13:g.55229255G>A, NC_000007.14:g.55161562G>A, NG_007726.3:g.147531G>A, NM_005228.3:c.1562G>A, NM_201282.1:c.1562G>A, NM_201284.1:c.1562G>A, NP_005219.2:p.Arg521Lys, NP_958439.1:p.Arg521Lys, NP_958441.1:p.Arg521Lys, XM_005271746.1:c.1427G>A, XM_005271747.1:c.1403G>A, XM_005271748.1:c.1562G>A, XP_005271803.1:p.Arg476Lys, XP_005271804.1:p.Arg468Lys, XP_005271805.1:p.Arg521Lys, rs11543848, rs117960725, rs12234746, rs17336807, rs3752650
G > A
SNP
R521K
No VIP available No Clinical Annotations available VA
rs2912024 NC_000008.10:g.6638899C>T, NC_000008.11:g.6781378C>T, rs56641910, rs57353971
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2928607 NC_000008.10:g.6638710C>G, NC_000008.11:g.6781189C>G
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2928608 NC_000008.10:g.6639024T>C, NC_000008.11:g.6781503T>C, rs58017964
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2928609 NC_000008.10:g.6639118T>C, NC_000008.11:g.6781597T>C, rs56794760
T > C
SNP
No VIP available No Clinical Annotations available VA
rs2936519 NC_000008.10:g.6639240G>A, NC_000008.11:g.6781719G>A, rs59917631
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2978926 NC_000008.10:g.6639425A>G, NC_000008.11:g.6781904A>G, rs56514514, rs57794753, rs58364937
A > G
SNP
No VIP available No Clinical Annotations available VA
rs2978931 NC_000008.10:g.6638081C>A, NC_000008.11:g.6780560C>A, rs386578178, rs59726576
C > A
SNP
No VIP available No Clinical Annotations available VA
rs35569394 unknown
No VIP available No Clinical Annotations available VA
rs3913032 NC_000004.11:g.75336859A>C, NC_000004.12:g.74471142A>C, rs60356243
A > C
SNP
No VIP available CA VA
rs396991 NC_000001.10:g.161514542A>C, NC_000001.11:g.161544752A>C, NG_009066.1:g.10872T>G, NM_000569.6:c.634T>G, NM_001127592.1:c.631T>G, NM_001127593.1:c.526T>G, NM_001127595.1:c.526T>G, NM_001127596.1:c.523T>G, NP_000560.5:p.Phe212Val, NP_001121064.1:p.Phe211Val, NP_001121065.1:p.Phe176Val, NP_001121067.1:p.Phe176Val, NP_001121068.1:p.Phe175Val, XM_011509293.1:c.428-1553T>G, rs17857127, rs2229097, rs3171040, rs4151086, rs61228128
A > C
SNP
F212V
No VIP available No Clinical Annotations available VA
rs4377367 NC_000002.11:g.131724905C>T, NC_000002.12:g.130967332C>T, NM_015320.3:c.427+20697C>T, NM_032995.2:c.427+20697C>T, XM_005263681.1:c.3985+20697C>T, XM_005263682.1:c.3874+20697C>T, XM_005263683.1:c.3985+20697C>T, XM_005263687.1:c.58+3083C>T, XM_005263687.2:c.58+3083C>T, XM_011511274.1:c.3985+20697C>T, XM_011511275.1:c.3949+20697C>T, XM_011511276.1:c.-55+20697C>T, XR_244821.1:n.4023+20697C>T, rs58214874
C > T
SNP
No VIP available CA VA
rs4444903 NC_000004.11:g.110834110A>G, NC_000004.12:g.109912954A>G, NG_011441.1:g.5071A>G, NM_001178130.2:c.-382A>G, NM_001178131.2:c.-382A>G, NM_001963.5:c.-382A>G, XM_005262796.1:c.-382A>G, XM_005262796.2:c.-382A>G, XM_005262797.1:c.-382A>G, XM_005262797.2:c.-382A>G, XM_005262798.1:c.-382A>G, XM_005262798.2:c.-382A>G, XM_005262799.1:c.-382A>G, XM_005262800.1:c.-382A>G, XM_005262800.2:c.-382A>G, XM_005262801.1:c.-382A>G, XM_005262801.2:c.-382A>G, XM_005262802.1:c.-382A>G, XM_005262802.2:c.-382A>G, XM_006714124.2:c.-382A>G, XM_011531707.1:c.-632A>G, XM_011531708.1:c.-382A>G, XM_011531709.1:c.-382A>G, XR_427532.2:n.72A>G, XR_938699.1:n.72A>G, rs58193687
A > G
SNP
No VIP available No Clinical Annotations available VA
rs4698803 NC_000004.11:g.110914427A>T, NC_000004.12:g.109993271A>T, NG_011441.1:g.85388A>T, NM_001178130.2:c.2735-1462A>T, NM_001178131.2:c.2633A>T, NM_001963.5:c.2759A>T, NP_001171602.1:p.Glu878Val, NP_001954.2:p.Glu920Val, XM_005262796.1:c.2759A>T, XM_005262796.2:c.2759A>T, XM_005262797.1:c.2633A>T, XM_005262797.2:c.2633A>T, XM_005262798.1:c.2516A>T, XM_005262798.2:c.2516A>T, XM_005262799.1:c.2759A>T, XM_005262800.1:c.2516A>T, XM_005262800.2:c.2516A>T, XM_005262801.1:c.2491+9730A>T, XM_005262801.2:c.2491+9730A>T, XM_006714124.2:c.2759A>T, XM_011531707.1:c.2648A>T, XM_011531708.1:c.2734+4562A>T, XP_005262853.1:p.Glu920Val, XP_005262854.1:p.Glu878Val, XP_005262855.1:p.Glu839Val, XP_005262856.1:p.Glu920Val, XP_005262857.1:p.Glu839Val, XP_006714187.1:p.Glu920Val, XP_011530009.1:p.Glu883Val, XR_427532.2:n.3187+4562A>T, XR_938699.1:n.3187+4562A>T, rs17253807, rs52809851, rs58275734
A > T
SNP
E878V
No VIP available CA VA
rs61764370 NC_000012.11:g.25360224A>C, NC_000012.12:g.25207290A>C, NG_007524.1:g.48631T>G, NM_004985.4:c.*2505T>G, NM_033360.3:c.*2626T>G, XM_011520653.1:c.*2505T>G, rs200812391
A > C
SNP
No VIP available No Clinical Annotations available VA
rs6447003 NC_000004.11:g.75386914G>C, NC_000004.12:g.74521197G>C, NW_003571035.1:g.4705G>C, rs17476698, rs61199787
G > C
SNP
No VIP available No Clinical Annotations available VA
rs6533485 NC_000004.11:g.110927563G>C, NC_000004.12:g.110006407G>C, NG_011441.1:g.98524G>C, NM_001178130.2:c.3169-1745G>C, NM_001178131.2:c.3166-1745G>C, NM_001963.5:c.3292-1745G>C, XM_005262796.1:c.3292-1745G>C, XM_005262796.2:c.3292-1745G>C, XM_005262797.1:c.3166-1745G>C, XM_005262797.2:c.3166-1745G>C, XM_005262798.1:c.3049-1745G>C, XM_005262798.2:c.3049-1745G>C, XM_005262800.1:c.3048+1785G>C, XM_005262800.2:c.3048+1785G>C, XM_005262801.1:c.2492-4795G>C, XM_005262801.2:c.2492-4795G>C, XM_006714124.2:c.3291+1785G>C, XM_011531707.1:c.3181-1745G>C, XR_427532.2:n.3305+1785G>C, XR_938699.1:n.3306-1745G>C
G > C
SNP
No VIP available No Clinical Annotations available VA
rs6850557 NC_000004.11:g.110911015G>A, NC_000004.12:g.109989859G>A, NG_011441.1:g.81976G>A, NM_001178130.2:c.2734+1150G>A, NM_001178131.2:c.2608+1150G>A, NM_001963.5:c.2734+1150G>A, XM_005262796.1:c.2734+1150G>A, XM_005262796.2:c.2734+1150G>A, XM_005262797.1:c.2608+1150G>A, XM_005262797.2:c.2608+1150G>A, XM_005262798.1:c.2492-3388G>A, XM_005262798.2:c.2492-3388G>A, XM_005262799.1:c.2734+1150G>A, XM_005262800.1:c.2492-3388G>A, XM_005262800.2:c.2492-3388G>A, XM_005262801.1:c.2491+6318G>A, XM_005262801.2:c.2491+6318G>A, XM_006714124.2:c.2734+1150G>A, XM_011531707.1:c.2623+1150G>A, XM_011531708.1:c.2734+1150G>A, XR_427532.2:n.3187+1150G>A, XR_938699.1:n.3187+1150G>A
G > A
SNP
No VIP available CA VA
rs712829 NC_000007.13:g.55086755G>T, NC_000007.14:g.55019062G>T, NG_007726.3:g.5031G>T, NM_005228.3:c.-216G>T, NM_201282.1:c.-216G>T, NM_201283.1:c.-216G>T, NM_201284.1:c.-216G>T, XM_005271746.1:c.-216G>T, XM_005271748.1:c.-216G>T, rs17288931
G > T
SNP
No VIP available CA VA
rs712830 NC_000007.13:g.55086780A>C, NC_000007.14:g.55019087A>C, NG_007726.3:g.5056A>C, NM_005228.3:c.-191A>C, NM_201282.1:c.-191A>C, NM_201283.1:c.-191A>C, NM_201284.1:c.-191A>C, XM_005271746.1:c.-191A>C, XM_005271748.1:c.-191A>C, rs17288938
A > C
SNP
No VIP available No Clinical Annotations available VA
rs7687621 NC_000004.11:g.75249826T>C, NC_000004.12:g.74384109T>C, NM_001432.2:c.429-618T>C, rs60629826
T > C
SNP
No VIP available No Clinical Annotations available VA
rs833061 NC_000006.11:g.43737486C>T, NC_000006.12:g.43769749C>T, NG_008732.1:g.4534C>T, NM_001025366.2:c.-958C>T, NM_001025367.2:c.-958C>T, NM_001025368.2:c.-958C>T, NM_001025369.2:c.-958C>T, NM_001025370.2:c.-958C>T, NM_001033756.2:c.-958C>T, NM_001171622.1:c.-958C>T, NM_001171623.1:c.-1498C>T, NM_001171624.1:c.-1498C>T, NM_001171625.1:c.-1498C>T, NM_001171626.1:c.-1498C>T, NM_001171627.1:c.-1498C>T, NM_001171628.1:c.-1498C>T, NM_001171629.1:c.-1498C>T, NM_001171630.1:c.-1498C>T, NM_001204384.1:c.-1498C>T, NM_001204385.1:c.-958C>T, NM_001317010.1:c.-1498C>T, NM_003376.5:c.-958C>T, rs36208046, rs60746584
C > T
SNP
No VIP available CA VA
rs885036 NC_000002.11:g.99304794A>G, NC_000002.12:g.98688331A>G, NM_012214.2:c.95-9860T>C, XM_005263866.1:c.95-9860T>C, XM_005263867.1:c.-637-9860T>C, rs17448475, rs60397503
A > G
SNP
No VIP available No Clinical Annotations available VA
rs929446 NC_000004.11:g.110883344C>T, NC_000004.12:g.109962188C>T, NG_011441.1:g.54305C>T, NM_001178130.2:c.1312+203C>T, NM_001178131.2:c.1186+203C>T, NM_001963.5:c.1312+203C>T, XM_005262796.1:c.1312+203C>T, XM_005262796.2:c.1312+203C>T, XM_005262797.1:c.1186+203C>T, XM_005262797.2:c.1186+203C>T, XM_005262798.1:c.1312+203C>T, XM_005262798.2:c.1312+203C>T, XM_005262799.1:c.1312+203C>T, XM_005262800.1:c.1312+203C>T, XM_005262800.2:c.1312+203C>T, XM_005262801.1:c.1312+203C>T, XM_005262801.2:c.1312+203C>T, XM_005262802.1:c.1312+203C>T, XM_005262802.2:c.1312+203C>T, XM_006714124.2:c.1312+203C>T, XM_011531707.1:c.1201+203C>T, XM_011531708.1:c.1312+203C>T, XM_011531709.1:c.1312+203C>T, XR_427532.2:n.1765+203C>T, XR_938699.1:n.1765+203C>T, rs61627853
C > T
SNP
No VIP available CA VA
rs9344 NC_000011.10:g.69648142G>A, NC_000011.9:g.69462910G>A, NG_007375.1:g.12038G>A, NM_053056.2:c.723G>A, NP_444284.1:p.Pro241=, XM_006718653.2:c.747G>A, XP_006718716.1:p.Pro249=, rs1131451, rs11557586, rs17295377, rs17349816, rs17359282, rs17852153, rs2227951, rs3191361, rs59807553, rs603965
G > A
SNP
P241P
No VIP available CA VA
rs9996584 NC_000004.11:g.75421961A>G, NC_000004.12:g.74556244A>G, NW_003571035.1:g.39752A>G
A > G
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Anti EGFR
  • IMC-C225
  • cetuximab
Trade Names
  • Erbitux
  • Erbitux (ImClone Systems Inc)
Brand Mixture Names

PharmGKB Accession Id

PA10040

Type(s):

Drug

Description

Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

Source: Drug Bank

Indication

For treatment of EGFR-expressing metastatic colorectal cancer in patients who are refractory to other irinotecan-based chemotherapy regimens. Cetuximab is also indicated for treatment of squamous cell carcinoma of the head and neck in conjucntion with radiation therapy.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

Cetuximab binds to the epidermal growth factor receptor (EGFr) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and TGF alpha, thereby reducing their effects on cell growth and metastatic spread.

Source: Drug Bank

Pharmacology

Used in the treatment of colorectal cancer, cetuximab binds specifically to the epidermal growth factor receptor (EGFr, HER1, c-ErbB-1) on both normal and tumor cells. EGFr is over-expressed in many colorectal cancers. Cetuximab competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. Binding of cetuximab to the EGFr blocks phosphorylation and activation of receptor-associated kinases, resulting in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase secretion and reduced vascular endothelial growth factor production.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Half-Life

114 hrs

Source: Drug Bank

Toxicity

Single doses of cetuximab higher than 500 mg/m 2 have not been tested. There is no experience with overdosage in human clinical trials.

Source: Drug Bank

Chemical Properties

Chemical Formula

C6484H10042N1732O2023S36

Source: Drug Bank

Average Molecular Weight

145781.6000

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. EGFR Inhibitor Pathway, Pharmacodynamics
    Model non-tissue specific cancer cell displaying genes that may be involved in the treatment using epidermal growth factor receptor specific tyrosine kinase inhibitors or monoclonal antibodies.

External Pathways

Links to non-PharmGKB pathways.

PharmGKB contains no links to external pathways for this drug. To report a pathway, click here.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
C1QA (source: Drug Bank)
C1QB (source: Drug Bank)
C1QC (source: Drug Bank)
C1R (source: Drug Bank)
C1S (source: Drug Bank)
EGFR (source: Drug Bank)
FCGR1A (source: Drug Bank)
FCGR2A (source: Drug Bank)
FCGR2B (source: Drug Bank)
FCGR2C (source: Drug Bank)
FCGR3A (source: Drug Bank)
FCGR3B (source: Drug Bank)
No related drugs are available.

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Adenocarcinoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arrhythmias, Cardiac
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Arthritis, Rheumatoid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial Fibrillation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Attention Deficit Disorder with Hyperactivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bipolar Disorder
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Breast Neoplasms
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Non-Small-Cell Lung
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carcinoma, Renal Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Colonic Neoplasms
No Dosing Guideline available DL CA VA No VIP available No VIP available
Colorectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Crohn Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cystic Fibrosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Depression
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Diarrhea
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug Hypersensitivity
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Drug Toxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epilepsy
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Esophagitis
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
event-free survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Exanthema
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Gastrointestinal Stromal Tumors
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glioblastoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Glioma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Graft vs Host Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Heart Failure
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hemorrhage
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HIV Infections
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypercholesterolemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypereosinophilic Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hyperlipoproteinemia Type II
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inflammatory Bowel Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Kidney Transplantation
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Lymphocytic, Chronic, B-Cell
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Myeloid, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Nonlymphocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Leukemia, Promyelocytic, Acute
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lung Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lymphoma, Large-Cell, Anaplastic
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lymphoma, Non-Hodgkin
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Malaria
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Melanoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Muscular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mycoses
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myelodysplastic Syndromes
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Myocardial Infarction
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasm Metastasis
No Dosing Guideline available DL No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
nephrotoxicity
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Neutropenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ocular Hypertension
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ovarian Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
overall survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pain
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pancreatic Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Peripheral Vascular Diseases
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Precursor Cell Lymphoblastic Leukemia-Lymphoma
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
progression-free survival
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Disease, Chronic Obstructive
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pulmonary Fibrosis
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Rectal Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Schizophrenia
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Sjogren's Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stomach Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stroke
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thromboembolism
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thrombosis
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Thyroid Neoplasms
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tuberculosis, Pulmonary
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Tumor Lysis Syndrome
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Urinary Incontinence

Publications related to cetuximab: 56

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours. European journal of cancer (Oxford, England : 1990). 2016. Rowland Andrew, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
BRAF in metastatic colorectal cancer: the future starts now. Pharmacogenomics. 2015. Orlandi Armando. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab. Pharmacogenomics. 2015. Rollin Jérôme, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Allegra Carmen J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015. Schirripa M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2015. Sclafani F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival. Molecular and clinical oncology. 2015. Osumi Hiroki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015. Van Cutsem Eric, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Molecular biomarkers in colorectal carcinoma. Pharmacogenomics. 2015. Puerta-García Elena, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. PloS one. 2015. Pander Jan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Saridaki Zenia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. The pharmacogenomics journal. 2014. Loupakis F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association study of the let-7 miRNA-complementary site variant in the 3' untranslated region of the KRAS gene in stage III colon cancer (NCCTG N0147 Clinical Trial). Clinical cancer research : an official journal of the American Association for Cancer Research. 2014. Sha Dan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Epigenetic perspectives on cancer chemotherapy response. Pharmacogenomics. 2014. Liu Mou-Ze, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The involvement of Kras gene 3'-UTR polymorphisms in risk of cancer and influence on patient response to anti-EGFR therapy in metastatic colorectal cancer: a meta-analysis. OncoTargets and therapy. 2014. Ying Hou-Qun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Emerging landscape of oncogenic signatures across human cancers. Nature genetics. 2013. Ciriello Giovanni, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptor. Pharmacogenetics and genomics. 2013. Hodoglugil Ugur, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan. The pharmacogenomics journal. 2013. Sebio A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?. Genetics in medicine : official journal of the American College of Medical Genetics. 2013. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3'-untranslated region: its role in the efficacy of anti-EGFR-based therapy in metastatic colorectal cancer patients. Pharmacogenetics and genomics. 2013. Sebio Ana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. Pharmacogenomics. 2013. Weng Liming, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis. Cancer chemotherapy and pharmacology. 2013. Chen Jian, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. The pharmacogenomics journal. 2013. Negri F V, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Influence of KRAS p.G13D mutation in patients with metastatic colorectal cancer treated with cetuximab. Clinical colorectal cancer. 2012. Gajate Pablo, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan. Japanese journal of clinical oncology. 2012. Bando Hideaki, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A Novel Fully Automated Molecular Diagnostic System (AMDS) for Colorectal Cancer Mutation Detection. PloS one. 2013. Kitano Shiro, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012. Tejpar Sabine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and pharmacogenomics: role of mutational analysis in anti-cancer targeted therapy. The pharmacogenomics journal. 2012. Savonarola A, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Multifactorial pharmacogenetic analysis in colorectal cancer patients receiving 5-fluorouracil-based therapy together with cetuximab-irinotecan. British journal of clinical pharmacology. 2012. Etienne-Grimaldi Marie-Christine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity. The pharmacogenomics journal. 2011. Parmar S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics. 2011. Patterson Scott D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Hu-Lieskovan Siwen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Novel chemosensitive single-nucleotide polymorphism markers to targeted regimens in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. Kim Jin C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics. 2011. Becquemont Laurent, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetic tests in cancer chemotherapy: what physicians should know for clinical application. The Journal of pathology. 2011. Lee Soo-Youn, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer. BMC cancer. 2011. Dahan Laetitia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomic contribution to drug response. Cancer journal (Sudbury, Mass.). 2011. Watson Roshawn G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA. 2010. De Roock Wendy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. The pharmacogenomics journal. 2010. Graziano F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. The Lancet. Oncology. 2010. De Roock Wendy, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clinical pharmacology and therapeutics. 2010. Stegmeier F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers. Gastrointestinal cancer research : GCR. 2009. Yalçin Suayib. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics and biomarkers in colorectal cancer. The pharmacogenomics journal. 2009. Strimpakos A S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009. Allegra Carmen J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. The pharmacogenomics journal. 2009. Graziano F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
K-ras mutations and benefit from cetuximab in advanced colorectal cancer. The New England journal of medicine. 2008. Karapetis Christos S, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008. Graziano Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenetics of EGFR and VEGF inhibition. Drug discovery today. 2007. Pander Jan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cetuximab for the treatment of colorectal cancer. The New England journal of medicine. 2007. Jonker Derek J, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007. Zhang Wu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British journal of cancer. 2007. Di Fiore F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics. 2007. Vincenzi Bruno, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenetics and genomics. 2006. Zhang Wu, et al. PubMed

LinkOuts

GenBank:
J00228
Web Resource:
Wikipedia
National Drug Code Directory:
66733-948-23
DrugBank:
DB00002
Therapeutic Targets Database:
DNC000788
FDA Drug Label at DailyMed:
8bc6397e-4bd8-4d37-a007-a327e4da34d9

Clinical Trials

These are trials that mention cetuximab and are related to either pharmacogenetics or pharmacogenomics.

No trials found.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.